Drug
Linifanib clinical trials
Also written ABT-869.
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2011 (6)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 6 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 1
AbbVie (prior sponsor, Abbott) (7) · Abbott (7) · AbbVie (3) · Alcon Research (1) · Vanderbilt-Ingram Cancer Center (1) · BioGene Pharmaceutical Ltd. (1)
Often tested with
Tested in the same studies.
Carboplatin (1) · Paclitaxel (1) · Bevacizumab (1) · Ketoconazole (1) · Afatinib (1) · Axitinib (1) · Erlotinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses linifanib is read from its arms, and is right about nine times in ten.
Testing it · 20
- Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the EndometriosisWithdrawnPhase 1/2BioGene Pharmaceutical Ltd.NCT03481842Written as Linifanib
- A Phase 1 Study of ABT-869 in Subjects With Solid TumorsCompletedPhase 1AbbVieNCT00718380Written as ABT-869
- A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1AbbVieNCT01225302Written as Linifanib
- Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869CompletedPhase 1AbbVie (prior sponsor, Abbott)NCT00733187Written as ABT-869
- An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid TumorsCompletedPhase 1AbbVieNCT01413893Written as linifanib
- Linifanib in Treating Patients With Advanced, Refractory Colorectal CancerTerminatedPhase 2Vanderbilt-Ingram Cancer CenterNCT01365910Written as linifanib
- WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment ExaminationCompletedPhase 2Alcon ResearchNCT00992563Written as AL-39324 ophthalmic suspension
- Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal CancerCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00707889Written as ABT-869
- Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00716534Written as ABT-869
- Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00517790Written as ABT-869 0.10 mg/kg
- Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast CancerCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00645177Written as ABT-869
- Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00517920Written as ABT-869
- Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With SunitinibCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00486538Written as ABT-869
- A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.TerminatedPhase 1AbbottNCT01286974Written as [14C]linifanib
- Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)TerminatedPhase 3AbbottNCT01009593Written as ABT-869
- A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsTerminatedPhase 1AbbottNCT01506934Written as linifanib
- To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.CompletedPhase 1AbbottNCT01381341Written as linifanib
- Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid TumorsCompletedPhase 1AbbottNCT01401933Written as Linifanib
- A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)CompletedPhase 1AbbottNCT01114191Written as ABT-869
- Study of ABT-869 in Combination With Tarceva in Subjects With Solid TumorsWithdrawnPhase 1AbbottNCT00754104Written as ABT-869
Codes
What other systems call linifanib · ClinicalTrials.gg INT004968
- MeSH (NLM) C513486linifanibOne source NLM
- UNII (FDA) CO93X137CWLINIFANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q6554172linifanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71759LinifanibOne source FDA
- DrugBank DB06080One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C513486 | linifanib | One source NLM |
| UNII (FDA) | CO93X137CW | LINIFANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6554172 | linifanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71759 | Linifanib | One source FDA |
| DrugBank | DB06080 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.